Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax
- PMID: 15838066
- DOI: 10.7326/0003-4819-142-8-200504190-00008
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax
Abstract
Background: Weaponized Bacillus anthracis is one of the few biological agents that can cause death and disease in sufficient numbers to devastate an urban setting.
Objective: To evaluate the cost-effectiveness of strategies for prophylaxis and treatment of an aerosolized B. anthracis bioterror attack.
Design: Decision analytic model.
Data sources: We derived probabilities of anthrax exposure, vaccine and treatment characteristics, and their costs and associated clinical outcomes from the medical literature and bioterrorism-preparedness experts.
Target population: Persons living and working in a large metropolitan U.S. city.
Time horizon: Patient lifetime.
Perspective: Societal.
Intervention: We evaluated 4 postattack strategies: no prophylaxis, vaccination alone, antibiotic prophylaxis alone, or vaccination and antibiotic prophylaxis, as well as preattack vaccination versus no vaccination.
Outcome measures: Costs, quality-adjusted life-years, life-years, and incremental cost-effectiveness.
Results of base-case analysis: If an aerosolized B. anthracis bioweapon attack occurs, postexposure prophylactic vaccination and antibiotic therapy for those potentially exposed is the most effective (0.33 life-year gained per person) and least costly (355 dollars saved per person) strategy, as compared with vaccination alone. At low baseline probabilities of attack and exposure, mass previous vaccination of a metropolitan population is more costly (815 million dollars for a city of 5 million people) and not more effective than no vaccination.
Results of sensitivity analysis: If prophylactic antibiotics cannot be promptly distributed after exposure, previous vaccination may become cost-effective.
Limitations: The probability of exposure and disease critically depends on the probability and mechanism of bioweapon release.
Conclusions: In the event of an aerosolized B. anthracis bioweapon attack over an unvaccinated metropolitan U.S. population, postattack prophylactic vaccination and antibiotic therapy is the most effective and least expensive strategy.
Comment in
-
Being prepared: modeling the response to an anthrax attack.Ann Intern Med. 2005 Apr 19;142(8):667-8. doi: 10.7326/0003-4819-142-8-200504190-00016. Ann Intern Med. 2005. PMID: 15838074 No abstract available.
Summary for patients in
-
Summaries for patients. What is the most cost-effective way to protect people in the event of an anthrax terror attack?Ann Intern Med. 2005 Apr 19;142(8):I40. doi: 10.7326/0003-4819-142-8-200504190-00002. Ann Intern Med. 2005. PMID: 15838060 No abstract available.
Similar articles
-
Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.Biosecur Bioterror. 2012 Sep;10(3):264-79. doi: 10.1089/bsp.2011.0105. Epub 2012 Jul 30. Biosecur Bioterror. 2012. PMID: 22845046 Free PMC article.
-
Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.Arch Intern Med. 2007 Apr 9;167(7):655-62. doi: 10.1001/archinte.167.7.655. Arch Intern Med. 2007. PMID: 17420423
-
Summaries for patients. What is the most cost-effective way to protect people in the event of an anthrax terror attack?Ann Intern Med. 2005 Apr 19;142(8):I40. doi: 10.7326/0003-4819-142-8-200504190-00002. Ann Intern Med. 2005. PMID: 15838060 No abstract available.
-
Vaccines and bioterrorism: smallpox and anthrax.J Fam Pract. 2003 Jan;52(1 Suppl):S56-61. J Fam Pract. 2003. PMID: 12556279 Review.
-
Anthrax as a biological weapon, 2002: updated recommendations for management.JAMA. 2002 May 1;287(17):2236-52. doi: 10.1001/jama.287.17.2236. JAMA. 2002. PMID: 11980524 Review.
Cited by
-
Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.Biosecur Bioterror. 2012 Sep;10(3):264-79. doi: 10.1089/bsp.2011.0105. Epub 2012 Jul 30. Biosecur Bioterror. 2012. PMID: 22845046 Free PMC article.
-
Interaction of occupational and personal risk factors in workforce health and safety.Am J Public Health. 2012 Mar;102(3):434-48. doi: 10.2105/AJPH.2011.300249. Epub 2011 Nov 28. Am J Public Health. 2012. PMID: 22021293 Free PMC article.
-
A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.Protein J. 2008 Aug;27(5):292-302. doi: 10.1007/s10930-008-9137-0. Protein J. 2008. PMID: 18649128
-
Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar.Trop Med Infect Dis. 2021 Jun 11;6(2):101. doi: 10.3390/tropicalmed6020101. Trop Med Infect Dis. 2021. PMID: 34208006 Free PMC article.
-
Real-time polymerase chain reaction assay for rapid and sensitive detection of anthrax spores in spiked soil and talcum powder.Folia Microbiol (Praha). 2012 May;57(3):237-42. doi: 10.1007/s12223-012-0117-6. Epub 2012 Apr 17. Folia Microbiol (Praha). 2012. PMID: 22528297
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials